Utah Medical Products Inc. filings document formal disclosures for a Utah-incorporated medical device manufacturer whose common stock trades on Nasdaq under the symbol UTMD. Recent Form 8-K reports furnish quarterly and annual financial information, including sales, margins, earnings measures and exhibits containing the company's financial-performance releases.
The filing record also covers governance and capital-return matters. Definitive proxy materials describe director elections, auditor ratification, advisory executive-compensation votes and annual meeting procedures, while 8-K reports record stockholder voting results, board appointments, committee service, director compensation arrangements and quarterly dividend announcements.
Utah Medical Products, Inc. (UTMD) reported that its wholly owned subsidiary Femcare Ltd has purchased all of the common shares of UK-based Orion Medical Supplies Ltd, a niche assembler and distributor of Harm Reduction medical device kits primarily in the UK and Europe. Orion’s products are used in programs aimed at reducing blood borne infections, harmful drug litter, overdose injuries and deaths, and related social impacts among drug users.
UTMD states that Orion is a stable, profitable business expected to be accretive to financial results, adding about $6 million to current consolidated annual sales, with potential for geographic expansion. The purchase price was £3.6 million, paid from cash reserves. Orion’s operations will be moved into Femcare’s existing Romsey facilities to leverage existing infrastructure and dilute overhead as a percentage of UK sales. UTMD notes that outcomes are subject to forward‑looking risks, and additional acquisition-related risk factors will appear in its third quarter 2026 Form 10‑Q, expected to be filed by October 15.
Brandes Investment Partners, L.P. filed an amended Schedule 13G reporting a significant passive ownership position in Utah Medical Products Inc. Brandes is deemed the beneficial owner of 475,158 common shares, representing 14.92% of the outstanding class, held across mutual funds and other accounts it advises. Brandes reports shared voting power over 435,111 shares and shared dispositive power over 475,158 shares, with no sole voting or dispositive power. 218,681 shares, or 6.87% of the class, are held in the Brandes Small Cap Value Fund, a series of Datum One Series Trust. Brandes states that the filing does not constitute an admission that the reporting persons form a group.
Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation report beneficial ownership of 175,814 shares of Utah Medical Products Inc. common stock, representing 5.52% of the class as of June 30, 2026. Both entities have sole voting and dispositive power over these shares, with no shared power reported. Certain funds managed by Renaissance Technologies LLC have the right to receive dividends and proceeds from the sale of these securities. The filing is signed by Brian Felczak in his capacities as Chief Financial Officer and Vice President on August 13, 2026.
Utah Medical Products, Inc. reported weaker results for the quarter and first half ended June 30, 2026, with 2Q 2026 net sales of $8,529 thousand, down 14.3% from 2Q 2025, and 1H 2026 sales of $17,252 thousand, down 12.3%. Net income declined 11.9% in 2Q to $2,686 thousand and 13.1% in 1H to $5,290 thousand, while diluted EPS fell to $0.84 for 2Q and $1.66 for 1H.
The declines were driven mainly by the loss of two formerly largest customers, which accounted for most of the year-over-year sales decrease, only partially offset by limited new biopharma OEM sales. Management now projects full-year 2026 revenue to decline 10–13% versus 2025, versus an earlier expectation of flat sales. Litigation expenses rose to $935 thousand in 1H 2026 and U.S. tariffs on Filshie devices reduced gross margin.
Despite lower volumes, profitability metrics remain strong: 2Q 2026 gross margin was 55.8% and operating margin 31.1%. The balance sheet is conservative, with $87,528 thousand in cash and investments, no debt, a current ratio of 48.6, and working capital of $98,569 thousand. The company continued returning capital via $1,976 thousand in dividends (37% of 1H net income) and $206 thousand of open-market share repurchases.
Utah Medical Products reported weaker results for the quarter and first half ended June 30, 2026. Second‑quarter net sales were $8,529, down 14.3% from 2025, and first‑half sales were $17,252, down 12.3%, mainly from the loss of two large customers whose 2025 sales totaled $2,889. New biopharma OEM sales reached only $211 in 1H 2026. Net income was $2,686 in 2Q and $5,290 in 1H, declines of 11.9% and 13.1%, with diluted EPS of $0.844 and $1.661 respectively.
Despite lower volumes and higher U.S. litigation costs, profitability remained high: gross margin was 55.8% in 2Q and 58.2% in 1H, and adjusted EBITDA margin was 43.9% for 1H. Management now projects 2026 sales to fall 10–13% versus 2025 and expects 2026 litigation expense to remain below $1.6 million. The balance sheet stayed strong with $87,528 in cash and investments, no debt, a 48.6 current ratio, ongoing dividends equal to 37% of year‑to‑date net income, and modest share repurchases.
UTAH MEDICAL PRODUCTS INC director Paul O. Richins reported an indirect bona fide gift of 150 shares of Common Stock. The gift was valued at $73.07 per share based on the Form 4 disclosure. After this disposition, indirect holdings total 20,765 shares.
These shares are held through various accounts and entities, including a spouse's IRA, a son's account, the reporting person's IRA, and the Richins Family Trust, as described in the footnote. The transaction reflects a non-market gift transfer rather than an open-market sale.
UTAH MEDICAL PRODUCTS INC principal financial officer Brian Koopman reported a bona fide gift transfer of 50 shares of Common Stock. The gifted shares were valued at $66.27 per share for reporting purposes. Following the gift, he directly holds 782 shares of the company’s stock.
Brandes Investment Partners amended a Schedule 13G to report beneficial ownership in Utah Medical Products, Inc. The filing states Brandes beneficially owns 449,680 shares, representing 14.12% of the class, with 412,007 shares reflecting shared voting power.
The disclosure lists CUSIP 917488108 and the reporting person as Brandes Investment Partners, L.P. The amendment is signed by Glenn Carlson as Executive Director.
Utah Medical Products reported lower first-quarter 2026 results, with solid margins but declines in sales and earnings versus a strong prior year. Net sales were $8,722k, down 10.2% from $9,710k, mainly due to the loss of a major China blood pressure monitoring distributor and an OEM customer.
Net income was $2,604k versus $3,041k, a 14.4% decrease, and diluted EPS fell to $0.82 from $0.92, helped somewhat by share repurchases that reduced the share count. Despite lower profit, gross margin improved to 60.6% from 57.0% on a more favorable product mix and a standard cost adjustment.
The company generated $3,109k of operating cash flow (down from $4,464k), ended the quarter with $87,406k in cash and investments, no debt, and stockholders’ equity of $120,373k. Utah Medical Products repurchased 2,196 shares for $129k and paid $989k in dividends while maintaining a very high current ratio and emphasizing continued buybacks and dividends as capital allocation priorities.
Utah Medical Products, Inc. reported the results of its annual stockholder meeting held on May 1, 2026. Stockholders elected Ernst G. Hoyer and James H. Beeson as directors, with Beeson receiving 1,708,941 votes for and Hoyer 1,330,333 votes for, alongside broker non-votes on each proposal.
Stockholders also ratified the selection of Haynie & Co. as the company’s independent public accounting firm for the year ended December 31, 2026, with 2,753,278 votes for. On an advisory basis, stockholders approved the compensation of the company’s named executive officers, with 2,354,919 votes for. The company plans to continue holding annual advisory votes on executive compensation until at least the next required vote on the frequency of these votes.